BridgeBio Unveils Promising Acoramidis Data at ESC Congress
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for genetic diseases, is set to present important results on their investigational drug Acoramidis at the upcoming European Society of Cardiology (ESC) Congress 2025. This event will take place in Madrid, Spain from August 29 to September 1. The presentations promise to provide significant insights into the safety and efficacy of Acoramidis for patients suffering from transthyretin-mediated amyloidosis (ATTR-CM).
Highlights of the ESC Congress Presentation
The event will feature a rapid-fire oral presentation and two ePosters that convey compelling findings from the ATTRibute-CM study. Patients affected by ATTR-CM will benefit from these shared insights, particularly regarding the impact of Acoramidis on cardiovascular health. This announcement marks a significant milestone in BridgeBio's ongoing mission to alleviate the burden of genetic diseases.
Oral Presentation Details
Title: Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study
Presenter: Dr. Kevin Alexander from Stanford University School of Medicine
Schedule: Saturday, August 30 at 1:15 pm CEST / 7:15 am ET
ePoster Presentations
The ePosters will delve into:
- Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM
Presenter: Dr. Nitasha Sarswat of UChicago Medicine
Date: Sunday, August 31 at 4:15 pm CEST / 10:15 am ET - Acoramidis Has a Beneficial Effect Compared with Placebo on Change from Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM
Presenter: Dr. Julian Gillmore, University College London
Date: Saturday, August 29 at 3:15 pm CEST / 9:15 am ET
About Acoramidis
Acoramidis, branded as Attruby™, is a transthyretin stabilizer employed in the treatment of adult patients with wild-type or variant ATTR-CM. Its primary function lies in mitigating cardiovascular death and limiting hospitalizations related to cardiovascular issues. Through these mechanisms, Acoramidis aims to enhance the quality of life for thousands affected by this complex condition.
Understanding Safety and Efficacy
BridgeBio is committed to transparency regarding the safety profile of Acoramidis. Notably, common adverse reactions include mild diarrhea and upper abdominal pain, typically resolving without necessitating drug discontinuation. Importantly, discontinuation rates due to adverse events between Acoramidis and placebo are comparable, illustrating a favorable safety profile across diverse patient populations.
BridgeBio's Commitment to Genetic Medicine
Since its inception in 2015, BridgeBio has been at the forefront of biopharmaceutical innovation, developing transformative treatments for genetic diseases. The company is driven by a talented team dedicated to leveraging genetic insights to expedite the delivery of groundbreaking therapies. With a robust pipeline ranging from early-stage research to advanced clinical trials, BridgeBio stands at the precipice of a new era in the treatment of rare genetic conditions.
Staying Connected with BridgeBio
For those interested in following BridgeBio's advancements and staying updated on their innovative therapies, please visit bridgebio.com. You can also connect with us on various social media platforms, including LinkedIn, Twitter, Facebook, and YouTube, where we share the latest developments in our journey to improve patient outcomes.
Frequently Asked Questions
What is Acoramidis used for?
Acoramidis is indicated for the treatment of cardiomyopathy related to ATTR-CM in adults, aiming to reduce cardiovascular mortality and hospitalizations.
When will the presentations take place at the ESC Congress?
The oral presentation is scheduled for August 30, and the ePosters will be presented on August 29 and August 31.
Who is leading the presentations?
Dr. Kevin Alexander will present the oral data, while Drs. Nitasha Sarswat and Julian Gillmore will share their findings through ePosters.
How does Acoramidis work?
Acoramidis stabilizes transthyretin, thereby slowing the progression of the amyloid build-up in the heart, ultimately aiming to improve patients' cardiovascular health.
How does BridgeBio ensure safety in its treatments?
BridgeBio closely monitors adverse reactions during clinical trials to ensure participant safety and provides comprehensive safety information to healthcare providers.
